How to Choose Between NASDAQ and NYSE for Your US IPO

The decision between NASDAQ and the New York Stock Exchange (NYSE) for a US initial public offering is no longer a simple question of prestige versus liquidity. For China-incorporated issuers pursuing a US listing in 2025-2026, the choice has become a strategic calculation influenced by the US Securities and Exchange Commission’s (SEC) evolving enforcement priorities under the Holding Foreign Companies Accountable Act (HFCAA), the specific requirements of the Public Company Accounting Oversight Board (PCAOB) for audit firms in the PRC, and the structural nuances of Variable Interest Entity (VIE) and Cayman Islands holding company structures. A 2025 report from the SEC’s Division of Corporation Finance confirmed that 14 China-based issuers were flagged for incomplete PCAOB audit trail documentation in the first half of 2025 alone, up from 6 in the same period in 2023. This regulatory scrutiny directly impacts listing venue selection, as NASDAQ and NYSE apply differing listing standards for minimum public float, corporate governance, and independent director requirements under their respective rulebooks. The following analysis dissects the quantitative and qualitative factors—from minimum market capitalisation thresholds to post-IPO lock-up flexibility—that CFOs and sponsors must weigh when selecting a venue for a US IPO in the current cycle.

Listing Standards and Quantitative Thresholds: NASDAQ vs. NYSE

The primary distinction between NASDAQ and NYSE lies in their respective listing standards, which dictate the minimum financial and liquidity metrics an issuer must satisfy. For a Main Board listing, NASDAQ operates under three distinct tiers—the NASDAQ Global Select Market (NGSM), the NASDAQ Global Market (NGM), and the NASDAQ Capital Market (NCM)—each with separate entry requirements. The NYSE, by contrast, maintains a single set of domestic listing standards under Section 102 of the NYSE Listed Company Manual, with alternative standards for international issuers under Section 103.

Minimum Market Capitalisation and Financial Tests

For a standard IPO on the NASDAQ NGSM, the issuer must satisfy at least one of four financial tests: the Earnings Test (aggregate pre-tax earnings of USD 11 million over the last three fiscal years, with each of the last two years at least USD 2.2 million), the Market Capitalisation with Revenue Test (market capitalisation of at least USD 550 million and total revenue of at least USD 100 million in the most recent fiscal year), the Market Capitalisation with Equity Test (market capitalisation of at least USD 850 million and stockholders’ equity of at least USD 90 million), or the Total Assets/Total Revenue Test (total assets of at least USD 80 million and total revenue of at least USD 90 million). These thresholds, codified in NASDAQ Listing Rule 5405, require a minimum public float of 1.1 million shares and a minimum of 450 round lot shareholders.

The NYSE domestic standards under Section 102.01B require an issuer to meet either the Earnings Test (aggregate pre-tax earnings of USD 10 million over the last three fiscal years, with each of the last two years at least USD 2 million) or the Market Capitalisation with Revenue Test (global market capitalisation of at least USD 750 million and revenue of at least USD 75 million in the most recent fiscal year). Critically, the NYSE imposes a minimum public float of USD 40 million for the Earnings Test and USD 100 million for the Market Capitalisation with Revenue Test, compared to NASDAQ’s more permissive USD 15 million public float requirement under Rule 5405(b)(3). For a China-based VIE issuer with a typical Cayman Islands holding company and a PRC operating entity, the NYSE’s higher public float threshold can be a binding constraint if the secondary offering size is limited by PRC securities regulator approval timelines.

Corporate Governance and Independent Director Requirements

Both exchanges mandate a majority of independent directors on the board, but the definition of independence under NASDAQ Rule 5605(a)(2) and NYSE Section 303A.01 differs in material respects. NASDAQ requires a board audit committee of at least three members, each of whom must be independent under Rule 5605(c)(2), and the audit committee must include at least one “audit committee financial expert” as defined by the SEC. The NYSE, under Section 303A.07, requires a similar audit committee composition but imposes a stricter “bright-line” test for independence that disqualifies directors who have received more than USD 120,000 in direct compensation from the issuer in any 12-month period (excluding board and committee fees). For a PRC-based issuer where a founding family member or a state-owned enterprise representative may serve on the board, the NYSE’s compensation-based independence test can be more restrictive than NASDAQ’s “material relationship” standard under Rule 5605(a)(2).

Listing Fees, Ongoing Costs, and Sponsor Economics

The direct cost of listing—including initial listing fees, annual fees, and the sponsor’s underwriting spread—varies significantly between the two venues. Data from the exchanges’ 2025 fee schedules and Dealogic’s underwriting fee database for 2024 provide a clear comparative framework.

Initial Listing Fees and Annual Fees

The NYSE charges an initial listing fee of USD 150,000 for the first 50 million shares, plus USD 0.0005 per additional share, with a maximum of USD 295,000 for domestic issuers. For international issuers listing under Section 103, the NYSE imposes a flat fee of USD 250,000. NASDAQ’s initial listing fee for the NGSM is a flat USD 295,000, with no per-share component. The annual fee differential is more pronounced: the NYSE charges an annual fee of USD 60,000 plus USD 0.00035 per share, capped at USD 500,000, while NASDAQ charges a flat annual fee of USD 55,000 for the NGSM. For a mid-cap issuer with 100 million shares outstanding, the NYSE annual fee would be approximately USD 95,000, compared to NASDAQ’s USD 55,000—a saving of USD 40,000 per year. These figures are sourced from the NYSE 2025 Fee Schedule (Section 902.01) and NASDAQ Listing Rule 5905.

Underwriting Spreads and Sponsor Economics

The underwriting spread for a US IPO typically ranges from 5.0% to 7.0% of gross proceeds, with the median spread for China-based issuers in 2024 at 6.5%, according to data from the S&P Capital IQ IPO database. The NYSE has historically commanded a slightly lower median spread (6.25%) for issuers above USD 100 million in market capitalisation, compared to NASDAQ’s median of 6.75% for the same cohort, reflecting the NYSE’s perception as a venue for larger, more liquid listings. However, for issuers below USD 50 million in market capitalisation, the spread differential narrows to approximately 50 basis points (bps). The sponsor’s decision to recommend one venue over another is influenced by the syndicate’s ability to place shares with institutional investors: the NYSE’s designated market maker (DMM) system provides a single point of liquidity and price discovery, while NASDAQ’s electronic market maker system relies on a competitive dealer network. For a China-based issuer with a concentrated shareholder base and limited US institutional investor relationships, the NYSE’s DMM model may reduce volatility in the first 30 trading days by 15-20% compared to NASDAQ, based on a 2024 study by the NYSE’s internal research unit.

Regulatory and Structural Considerations for China-Based Issuers

The choice between NASDAQ and NYSE is not solely a financial calculation; it is heavily influenced by the regulatory framework governing China-based issuers under the HFCAA, the PCAOB’s inspection regime, and the PRC’s own securities laws under the 2023 revised Securities Law of the PRC.

PCAOB Inspection Compliance and Audit Trail Requirements

Since the PCAOB regained full inspection access to PRC-based audit firms in December 2022 under the HFCAA, the SEC has maintained a heightened scrutiny of audit workpapers for China-based issuers. A 2025 PCAOB staff report noted that 8% of inspected PRC audit engagements contained deficiencies in audit documentation related to revenue recognition and related-party transactions, compared to 4% for US-based engagements. The NYSE’s listing standards under Section 102.01B require issuers to file annual reports on Form 20-F within four months of fiscal year-end, while NASDAQ’s Rule 5250(c)(1) imposes the same deadline. However, the NYSE has historically been more lenient in granting extensions for audit completion under Section 802.01E of the NYSE Listed Company Manual, allowing up to 30 additional days for issuers that demonstrate a good-faith effort to comply with PCAOB requirements. For a China-based issuer with a complex VIE structure and multiple PRC subsidiaries, the NYSE’s extension policy can be a critical buffer against a potential delisting risk if the PCAOB inspection is delayed.

PRC Securities Law Compliance and the CSRC Filing Regime

Under the PRC Securities Law (2023 revision) and the China Securities Regulatory Commission’s (CSRC) Administrative Provisions on Overseas Securities Offering and Listing (effective 31 March 2023), all China-based issuers seeking a US listing must file a confidential registration statement with the CSRC at least 20 business days before the SEC filing. The CSRC’s review focuses on the legality of the VIE structure, the control over variable interest entities, and the absence of national security risks under the Cybersecurity Review Measures (2022). As of mid-2025, the CSRC has approved 34 US IPO filings, with an average review period of 45 calendar days. The NYSE has processed 18 of these filings, while NASDAQ has processed 16. The CSRC has not publicly differentiated its approval criteria by venue, but market participants report that the NYSE’s more stringent corporate governance requirements (e.g., the USD 120,000 compensation independence test) align more closely with the CSRC’s expectations for independent director oversight. This alignment may reduce the risk of a CSRC rejection or a request for additional documentation, which has occurred in 3 cases in 2024-2025, according to CSRC public filings.

VIE Structure and Shareholder Rights

The VIE structure, which remains the predominant vehicle for China-based issuers in the US, introduces specific listing considerations. Under NASDAQ Rule 5250(b)(3), issuers must disclose any material differences between the voting rights of public shareholders and those of insiders. The NYSE’s Section 303A.08 requires a similar disclosure but also mandates a shareholder vote on any issuance that would dilute existing shareholders by more than 20% of outstanding shares. For a VIE issuer where the PRC operating entity’s equity is held by a domestic shareholder (often the founder) under contractual arrangements, the NYSE’s anti-dilution rule provides stronger protection for minority public shareholders. This has become a factor in sponsor selection, as institutional investors—particularly US mutual funds and pension funds—increasingly demand anti-dilution protections in VIE structures. A 2025 survey by the Council of Institutional Investors found that 72% of respondents would require an anti-dilution provision for any VIE-based IPO, up from 55% in 2022.

Market Mechanics, Liquidity, and Post-IPO Performance

The operational mechanics of trading on each venue—including the role of the designated market maker (NYSE) versus the electronic market maker network (NASDAQ)—directly affect post-IPO liquidity, price stability, and the cost of capital for secondary offerings.

Liquidity and Bid-Ask Spreads

Empirical data from the 2024 calendar year, published by the NYSE and NASDAQ in their respective market quality reports, shows that the average bid-ask spread for NYSE-listed China-based issuers was 12.5 bps, compared to 15.8 bps for NASDAQ-listed comparables. This 330 bps differential is attributable to the NYSE’s DMM system, which provides a single, committed liquidity provider for each listed security, versus NASDAQ’s competitive dealer system, where multiple market makers can quote but are not obligated to maintain continuous two-sided markets. For a mid-cap issuer with an average daily trading volume of USD 10 million, a 3.3 bps reduction in bid-ask spread translates to an annual liquidity cost saving of approximately USD 825,000 for institutional investors. This metric is critical for family offices and long-only funds that hold positions for 12-24 months.

Post-IPO Lock-Up Expiry and Price Impact

The standard lock-up period for a US IPO is 180 days from the effective date, under SEC Rule 144. However, both exchanges allow for early release of lock-up shares under specific conditions. The NYSE’s Section 703.01 permits a waiver of the lock-up for up to 10% of outstanding shares if the issuer provides a written undertaking to maintain a minimum public float of USD 40 million. NASDAQ’s Rule 5250(b)(1) does not provide a comparable waiver mechanism, meaning that any early release requires a formal amendment to the underwriting agreement. For a China-based issuer where insiders hold a concentrated stake (often 60-80% of total shares), the NYSE’s lock-up waiver provision can facilitate a secondary offering at a lower discount to the market price. Data from Dealogic shows that NYSE-listed issuers achieved a median discount of 3.5% on secondary offerings within 12 months of IPO, compared to 5.2% for NASDAQ-listed issuers, reflecting the NYSE’s more flexible lock-up regime.

Index Inclusion and Institutional Ownership

The NYSE’s historical status as the primary venue for large-cap listings has resulted in higher institutional ownership for NYSE-listed China-based issuers. As of Q1 2025, the average institutional ownership percentage for NYSE-listed China-based ADRs was 68%, compared to 54% for NASDAQ-listed comparables, according to data from Bloomberg. This differential is partly driven by index inclusion: the S&P 500, which is weighted toward NYSE-listed stocks, has a lower threshold for NYSE inclusion under the S&P Dow Jones Indices methodology, which requires a minimum market capitalisation of USD 14.5 billion and a public float of at least 50%. For a China-based issuer targeting inclusion in the MSCI China Index or the FTSE China Index, the venue choice has a material impact on the probability of inclusion. The MSCI China Index, as of its May 2025 semi-annual review, included 14 NYSE-listed issuers and 9 NASDAQ-listed issuers among its 72 constituents, reflecting a structural bias toward the NYSE for larger issuers.

Actionable Takeaways

1. For issuers with a market capitalisation below USD 300 million, NASDAQ’s lower public float threshold (USD 15 million vs. NYSE’s USD 40-100 million) and flat annual fee of USD 55,000 make it the cost-efficient choice, provided the issuer can meet the NGSM’s Earnings Test of USD 11 million aggregate pre-tax income over three years.

2. The NYSE’s DMM system reduces post-IPO bid-ask spreads by an average of 330 bps for China-based issuers, translating to material liquidity cost savings for institutional investors; this advantage is most pronounced for issuers with an expected average daily trading volume above USD 5 million.

3. PRC-based VIE issuers should prioritise the NYSE if the CSRC’s review timeline is a binding constraint, as the NYSE’s 30-day audit extension policy under Section 802.01E provides a regulatory buffer that NASDAQ’s Rule 5250 does not offer.

4. The NYSE’s anti-dilution rule under Section 303A.08, requiring a shareholder vote for any issuance exceeding 20% of outstanding shares, provides stronger minority shareholder protection and aligns with institutional investor expectations for VIE structures.

5. The lock-up waiver mechanism under NYSE Section 703.01 allows for early release of up to 10% of outstanding shares without a formal underwriting amendment, enabling secondary offerings at a lower median discount (3.5%) compared to NASDAQ (5.2%).